After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
- 1 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 38 (3), 247-257
- https://doi.org/10.1007/s40273-019-00882-6
Abstract
The National Institute for Health and Care Excellence (NICE) is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. However, it can be argued that NICE has developed a more prominent international profile than most in their use of economics. After 20 years of operation, it is timely to assess the extent of NICE's achievements, including the economic evaluation methods it has used and its willingness to adapt these as new evaluative approaches emerge and when NICE faces particular policy challenges. This paper considers some of the important policy and contextual developments in the UK over the last 20 years and how these may have shaped NICE's approach to economic evaluation. It then assesses key areas of NICE methods, including perspective, defining benefits, modelling and uncertainty. The paper concludes that NICE has provided important support for the development of new methods, in particular through its role in identifying priorities for methods research funding and its sponsorship of the NICE Decision Support Unit. However, potentially important developments in methods in a number of important areas have yet to be formally included in NICE's methods guidance and this should be addressed in the Institute's 2019/2020 methods review.This publication has 33 references indexed in Scilit:
- Evidence Synthesis for Decision Making 6Medical Decision Making, 2013
- Model Parameter Estimation and Uncertainty AnalysisMedical Decision Making, 2012
- SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAINHealth Economics, 2012
- A Framework for Addressing Structural Uncertainty in Decision ModelsMedical Decision Making, 2011
- Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical ExcellenceInternational Journal of Technology Assessment in Health Care, 2011
- Ten arguments for a societal perspective in the economic evaluation of medical innovationsThe European Journal of Health Economics, 2009
- NICE's use of cost effectiveness as an exemplar of a deliberative processHealth Economics, Policy and Law, 2006
- Orphan drugs and the NHS: should we value rarity?BMJ, 2005
- Probabilistic sensitivity analysis for NICE technology assessment: not an optional extraHealth Economics, 2005
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994